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Over the past two decades, management of newly diagnosed glioblastoma has undergone
signiﬁcant evolution.While surgery has long been a mainstay of management for this dis-
ease, and while radiotherapy has a proven survival role, initial efforts at radiotherapy dose
escalation, use of radiosurgery, brachytherapy, and altered fractionation did not improve
patient survival. Recently, multiple modality therapy integrating maximal safe resection,
postoperative radiation, and new systemic therapies have resulted in improved patient out-
comes compared with older regimens utilizing surgery and postoperative radiation alone.
Numerous trials are currently underway investigating the combination of surgery, radiation,
and systemic therapy with targeted agents to ﬁnd ways to further improve outcomes for
adults with glioblastoma.
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INTRODUCTION
Glioblastoma (GBM) remains a highly lethal and aggressive tumor
with dismal prognosis. Malignant astrocytomas constitute around
80% of all gliomas, with WHO grade IV glioma or glioblastoma
representing the vast majority of high-grade gliomas (Jukich et al.,
2001;Wrensch et al., 2002; Black andLoefﬂer, 2005).Until recently,
long-term survivors of glioblastoma were exceedingly rare, with
5-year survival of 5% or less (Chandler et al., 1993).
Level 1 evidence supporting a categorical role for complete
surgical resection does not exist, in part due to the impossibil-
ity of performing a trial in which patients could prospectively
be randomized to gross total resection versus lesser resection.
Therefore, this issue remains controversial. Indirect evidence in
support of more complete versus less complete resection comes
from trials such as the one conducted by Vuorinen et al., which
showed a survival beneﬁt to tumor resection over biopsy alone in
elderly patients, albeit with no difference in time to deterioration
between the two groups.We recognize that this does not constitute
deﬁnitive evidence in support of more complete resection yielding
improved survival; however the conventional practice approach is
to perform as complete a resection as safely possible (Vuorinen
et al., 2003). Immediate postoperative contrast-enhanced MRI
following resection of glioblastoma, generally performed within
72 h or less (to avoid the confounding postoperative changes that
start soon after surgery) often demonstrates residual enhancement
surrounding the resection cavity, an area along with postoper-
ative edema becomes an important target for radiotherapy. A
recent phase III study using 5-aminolevulinic acid (5-ALA) for
ﬂuorescence-guided resection showed an almost 20% improve-
ment in 6-month progression-free survival comparedwith tumors
resected under white light alone, underscoring the importance
of complete resection in these highly inﬁltrative tumors whose
borders are difﬁcult to discern (Stummer et al., 2006). By using
5-ALA, contrast enhancing tumor was completely resected in
65% of patients versus in 36% of control patients. As alluded to
earlier, there are insufﬁcient level 1 data to conclude that complete
resection imparts a survival beneﬁt; however, in a large single insti-
tutional analysis of all GBM patients undergoing resection, with
each patient having comprehensive prospective data storage,when
the extent of resection exceeded 98%of all enhancing tumor, a sur-
vival beneﬁt of approximately 5months started to emerge (Lacroix
et al., 2001).
ROLE OF POSTOPERATIVE RADIOTHERAPY
The Brain Tumor Study Group trial was one of the earliest ran-
domized studies to show a survival advantage with postoperative
radiotherapy versus best supportive care in patients with anaplas-
tic gliomas (90% of whom had glioblastoma; Table 1;Walker et al.,
1978). Study arms included BCNU alone, radiation alone, com-
bined BCNU and radiation, and supportive care. Patients who
received postoperative radiation had a median survival of 37.5
versus 17weeks for supportive care. The combination of BCNU
and radiation resulted in median survival of 40.5 weeks, not statis-
tically different from radiotherapy alone.All arms were superior to
supportive care. Of note, in this and other early studies, fraction-
ated radiation was delivered to the whole brain in doses of over
50Gy. A randomized study of radiotherapy versus best supportive
care by Andersen (1978) showed a 6-month survival rate of 64%
in the irradiated group versus 28% without radiation. Another
study by Walker et al. (1980) randomized patients with malignant
glioma to either semustine alone, radiation alone, semustine and
radiation, or BCNU and radiation. Patients receiving radiotherapy
had signiﬁcantly longer survival thanpatientswho received semus-
tine alone. Kristiansen et al. (1981) randomized 118 patients with
grade 3 and 4 astrocytoma to radiation, radiation and bleomycin,
or supportive care and found a median survival of 10.2months
with radiation alone compared to 5.2monthswith supportive care.
Although no randomized data are available directly compar-
ing whole brain to partial brain radiation, one intergroup study
changed the ﬁeld set-up from whole brain to whole brain plus a
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Table 1 | Role of radiotherapy in glioblastoma.
Author N Schema Results
Andersen (1978) 108 RT versus best supportive care Post-op RT signiﬁcantly improves survival compared
to best supportive care
Walker et al. (1978) 303 BCNU versus RT versus BCNU+RT versus best
supportive care
Patients receiving RT had longer MS than patients
receiving BCNU or best supportive care
Walker et al. (1980) 467 Semustine versus RT versus semustine+RT versus
BCNU+RT
Patients receiving RT had longer survival than patients
receiving semustine alone
Kristiansen et al. (1981) 118 RT versus RT+bleomycin versus best supportive care Median survival with RT alone 10.2 versus 5.2months
with best supportive care
Chang et al. (1983) 538 RT 60Gy versus RT 70Gy versus RT 60Gy+BCNU
versus RT 60Gy+methyl-CCNU+dacarbazine
Dose escalation beyond 60Gy or the addition of
chemotherapy did not improve survival outcomes and
BCNU did not improve overall or median survival
partial brain boost during the study period (Shapiro et al., 1989).
Patients were randomized to one of three BCNU-containing
chemotherapy regimens,and all patients received radiation.Of 571
enrolled patients, eighty percent had glioblastoma. Those enrolled
in 1980 or 1981 received 60.2Gy radiation to the whole brain, and
those enrolled later received 43Gy to the whole brain followed by a
17.2-Gy tumor volume boost. No statistically signiﬁcant difference
in survival was observed between the two radiotherapy regimens.
Consequently, an approach of treating a larger volume encom-
passing the “edema” which putatively also includes microscopic
extension, and is best visualized on MR FLAIR or T2 sequences
to approximately 46Gy followed by a boost to the enhancing
residual disease and surgical cavity to 60Gy has become a widely
used “standard.” More recently, several institutions have adopted
further margin modiﬁcations but without formal randomized
comparisons (Chang et al., 2007).
Several studies have examined dose escalation in an attempt
to improve local control and survival. A pooled analysis of three
randomized trials from the Brain Tumor Study Group showed
improved survival as dose was increased from 45 to 60Gy (Walker
et al., 1979). Further dose escalation beyond 60Gy was attempted
in a joint RTOG/ECOG four-arm randomized trial (Chang et al.,
1983; Nelson et al., 1988). Patients received 60Gy alone in the
control arm, 60Gy with one of two nitrosourea regimens in two
combined modality arms, or 60Gy with the addition of a 10-Gy
boost in the ﬁnal arm. No signiﬁcant difference in survival was
noted for any of the experimental arms over the control arm. The
University of Michigan conducted a phase I dose escalation trial,
and at the top dose of 90Gy, treated 34 malignant glioma patients
with 3-D conformal intensity modulation (Chan et al., 2002).
Despite the higher dose, median survival was only 11.7months,
and failures were primarily local. Of the patients who recurred,
9% experienced marginal or distant recurrences. In a recent paper
byNieder et al., the authors suggest revisiting dose escalation based
on the hypothesis that the success of temozolomide concurrently
with radiotherapy may provide the increased radiosensitivity and
improvement in local control of microscopic disease required to
observe a treatment effect from dose escalation. Furthermore, the
authors suggest that identifying molecular signatures of radiore-
sistant tumors as well as utilization of targeted agents may reveal
a population of patients who could beneﬁt from dose escalation
strategies (Nieder and Mehta, 2011).
Altered fractionation has also been studied in several random-
ized studies. Prados et al. (2001) studied an accelerated hyper-
fractionation schedule of 70.4Gy in 1.6Gy fractions twice daily
compared with 59.4Gy at 1.8 Gy per day. Patients were random-
ized to either of these radiation techniques and to treatment with
the radiosensitizer diﬂuoromethylornithine.Neither the sensitizer,
nor the hyperfractionation regimen demonstrated an overall sur-
vival or progression-free survival beneﬁt. RTOG 90-06 similarly
found no survival difference between 72Gy at 1.2 Gy twice daily
and 60Gy conventionally fractionated, both given concurrently
with carmustine (Scott et al., 1998). A meta-analysis of altered
fractionation by Nieder et al. (2004) showed that although treat-
ment time was decreased, no survival beneﬁt was observed. As a
result of these and similar studies, 60Gy has become an established
dose for conventional external beam radiotherapy in postoperative
treatment of newly diagnosed glioblastoma.
Radiosurgery has also been studied as a way to deliver a boost
dose in conjunction with a course of conventional chemoradia-
tion. In a randomized RTOG study, 203 patients with newly diag-
nosed glioblastoma less than or equal to 4 cm in size were random-
ized after surgery to an up-front radiosurgery boost or not, with
all patients receiving 60Gy partial brain radiation with concurrent
BCNU (Souhami et al., 2004). Radiosurgery doses varied from 15
to 24Gy depending on the target volume. Median survival in the
radiosurgery arm was 13.5months compared to 13.6months in
the conventional arm, and no differences in patterns of failure
between the two arms were observed.
Finally, brachytherapy has also been employed in an attempt
to decrease local failures, both with permanent and temporary
implants. Two randomized trials have been conducted for newly
diagnosed malignant gliomas. The Princess Margaret Hospital
randomized patients with malignant astrocytomas to 50Gy exter-
nal beam radiation or the same dose followed by 60Gy boost
via an I-125 implant (Laperriere et al., 1998). Tumors were less
than or equal to 6 cm in size and not crossing midline. No sig-
niﬁcant difference in survival was observed between treatment
groups. A second randomized trial reported by Selker et al. (2002)
was also negative. A new device, the GliaSite system, implants an
intracavitary balloon into the tumor cavity which is infused per-
cutaneously with an I-125 solution allowing delivery of 40–60Gy
over several days, after which the isotope is removed (Wernicke
et al., 2010).
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RADIATION SENSITIZERS AND MODULATORS
One strategy for increasing the efﬁcacy of radiation without
increasing physical dose involves the use of radiation sensitizers
or modulators. The halogenated pyrimidines, including bromod-
eoxyuridine (BUdR), and iododeoxyuridine (IUdR) are thymidine
analogs which become incorporated in DNA during synthesis and
function as S-phase radiosensitizers. RTOG 94-04 was a random-
ized study of external beam radiation with procarbazine, lomus-
tine, and vincristine (PCV) with or without BUdR for anaplastic
gliomas (Prados et al., 2004). The study showed no survival ben-
eﬁt for BUdR. IUdR has been studied in several GBM trials, with
no convincing evidence for superior efﬁcacy. Hypoxic sensitizers
such as nitroimidazoles and tirapazamine have failed to show efﬁ-
cacy. The Medical Research Council randomized patients who to
misonidazole or placebo with 45Gy radiotherapy and found no
difference in median survival between groupsAnonymous (1983).
Tirapazamine was administered with 60Gy of partial brain radi-
ation in RTOG 94-17, and comparison with RPA class controls
from RTOG again failed to demonstrate improved survival (Del
Rowe et al., 2000).
Initially applied to the treatment of brainmetastases,motexaﬁn
gadolinium (MGd) has also been studied in malignant gliomas.
MGd oxidizes intracellular redox metabolites necessary for DNA
damage repair thereby impairing strand-break repair, and it also
generates reactive oxygen species which are selectively concen-
trated in tumor cells, promoting apoptosis. An additional beneﬁt
of MGd is that cells which selectively uptake the compound can
be visualized by MRI since gadolinium is paramagnetic. A phase
I dose escalation trial investigating MGd demonstrated median
survival of 17.6months, leading to a phase II trial which has not
yet reported ﬁnal results (Ford et al., 2007). RSR13 is a novel
hypoxic sensitizer that increases oxygen unloading in hypoxic tis-
sue through allosteric hemoglobin modiﬁcation (Kleinberg et al.,
2002). This agent was administered in a phase II trial of 50
newly diagnosed glioblastoma patients, and median survival was
12.3months with a favorable toxicity proﬁle.
CYTOTOXIC CHEMOTHERAPY
Although numerous agents including topoisomerase inhibitors,
platinoids, and taxanes have beenusedbothwith andwithout radi-
ation, the most effective agent is temozolomide, FDA approved for
newly diagnosed GBM in 2005. Previously, alkylating agents were
frequently employed in the treatment of malignant gliomas. Taken
individually, each of these trials was negative. Fine et al. undertook
a meta-analysis of 16 randomized trials that included over 3000
patients and found a 10.1% increase in survival at 1 year and 8.6%
increase at 2 years with combination chemotherapy and radiation
over radiation alone. Median overall survival increased from 9.4
to 12months (Fine et al., 1993). An overview of other recent trials
with chemotherapy in the pre-temozolomide era is presented in
Table 2.
Polymer wafers impregnated with BCNU were developed to
increase exposure of tumor cells in the perioperative bed to local-
ized chemotherapy doses, bypass the blood–brain barrier, and
minimize systemic toxicities. A randomized trial of BCNU versus
placebo which included not only glioblastoma, but also anaplas-
tic gliomas demonstrated a signiﬁcant increase in median overall
survival of 13.9months with the BCNU wafers over 11.6months
in the placebo arm (Westphal et al., 2003). However, the wafers
have never been directly compared to conventional systemic
chemotherapy.
Temozolomide, a pro-drug, is an alkylating agent able to cross
the blood–brain barriers (Hegi et al., 2004).After the oral pro-drug
is converted to its active form at physiologic pH, the drug methy-
lates DNA at multiple sites, including guanine at the O-6 position
(a methylation event that occurs about 6 times out of every 100
DNA methylation events). Unless the methylation in this speciﬁc
location is repaired by a process involving the enzyme methylgua-
nine methyltransferase (MGMT), the active drug leads to double
strand breaks. The MGMT gene promoter itself can be hyperme-
thylated which results in epigenetic gene silencing and enzyme
inactivation with consequent increased sensitivity to temozolo-
mide (Hegi et al., 2005, 2009). The EORTC phase III randomized
trial of concurrent temozolomide and radiation versus radiation
alone showed a survival beneﬁt to the addition of temozolomide,
which was robustly sustained with long-term follow-up (Table 3;
Stupp et al., 2005). Patients with newly diagnosed glioblastoma
were randomized to 75mg/m2 of temozolomide given 7 days a
week, concurrent with radiation which was given 5 days a week.
Patients in the drug arm then received 6months of adjuvant ther-
apy for ﬁve out of every 28 days at a dose of 150–200mg/m2/d.
Median overall survival for temozolomide and radiation was 14.6
versus 12.1months for radiation alone. In a 2009 update, overall
survival at 2, 4, and 5 years with temozolomide and radiation was
reported to be 27.2, 12.1, and 9.8%, respectively, compared to 10.9,
3, and 1.9%with radiation alone, and the beneﬁt of treatment with
drug was noted in all prognostic subgroups (Stupp et al., 2009).
Methylation status of the MGMT gene promoter was the strongest
predictor of response and outcome. A retrospective analysis of tis-
sue samples generated data to support the role of MGMT in deter-
mining resistance to chemotherapy and radiotherapy. Among the
92 assessable cases with evidence of MGMTpromotermethylation
(i.e., transcriptionally inactive and not producing the DNA-repair
enzyme MGMT), a statistically signiﬁcant improvement in sur-
vival was observed in patients receiving temozolomide in combi-
nation with radiotherapy compared with radiotherapy alone (21.7
versus 15.3months, p = 0.007). Approximately 60% of patients in
the control arm received temozolomide at recurrence, and survival
among these patients with promoter methylation was signiﬁcantly
better than for patients with an unmethylated promoter (overall
survival 15.3 versus 11.8months, respectively). This trial provided
the ﬁrst convincing evidence of survival beneﬁt from the addi-
tion of chemotherapy to radiotherapy for patients with GBM.
Similar evidence for this trial comes fromaGreekphase II random-
ized trial (Athanassiou et al., 2005). Median time to progression
with radiation alone was 5.2months, similar to the EORTC/NCIC
study, compared to 10.8months after combined therapy, longer
than the 6.9-months in the EORTC/NCIC study.
The use of temozolomide has raised several unique issues
and questions. It has now been recognized that treatment with
temozolomide and radiotherapy may result in an increased fre-
quency of pseudoprogression which manifests on MR imaging
as an increase in contrast enhancement, possibly from alterations
in the blood–brain barrier, falsely suggesting tumor progression.
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Table 2 | Pre-temozolomide trials.
Author N Schema Results
Souhami et al. (2004) 203 60Gy RT versus 60Gy RT+SRS, both with concur-
rent BCNU
No difference in median survival
Buckner et al. (2006) 401 64.8Gy RT versus accelerated RT, both with BCNU
+/− cisplatin
No improvement in survival with accelerated RT or addition of
cisplatin
Fisher et al. (2002) 87 60Gy RT with topotecan Median survival 9months
Langer et al. (2001) 61 60Gy RT with paclitaxel Median survival 10months
Table 3 | GBM clinical trials with temozolomide.
Author N Schema Results
Stupp et al. (2005) 573 RT+temozolomide versus RT alone Overall survival for combined modality at 2 years 27.2%, 12.1% at 4 years, and
9.8% at 5 years versus 10.9, 3, and 1.9% for radiation alone
Athanassiou et al. (2005) 110 RT+temozolomide versus RT alone Median survival for combined modality 13 versus 8months for radiation alone
Kocher et al. (2008) 62 RT+temozolomide versus RT alone Median survival 15months for combined modality versus 17months for radiation
alone
Typically, response to therapy utilizes two dimensional size mea-
surements from CT and MRI imaging along with clinical response
and steroid use (Wen et al., 2010). However, recent awareness
has grown of limitations in focusing on contrast enhancement
to evaluate disease extent, particularly with the use of antian-
giogenic agents and recognition that enhancement is sometimes
non-speciﬁc. In one study, MGMT methylation was a signiﬁcant
predictor of increased likelihood of pseudoprogression (Brandes
et al., 2008). This may be a concern because patients with pseudo-
progression are sometimes deemed tohave true progression result-
ing in discontinuation of a possibly effective therapy, whereas in
reality patients with pseudoprogression may in fact have longer
survival compared to patients with no imaging changes.
A major unanswered question is the value of adjuvant temo-
zolomide; pre-clinical experiments suggest that the beneﬁt is
derived from the concomitant use with radiotherapy (Chakravarti
et al., 2006). Although the question has not been investigated in
a randomized trial, Combs et al. conducted a single agent trial of
temozolomide at 50mg/m2/day of during radiotherapy, without
the use of temozolomide in the adjuvant phase. Median overall
survival was 19months, with 1 and 2 year survival rates of 72 and
29%, comparable to the EORTC–NCIC trial results (Combs et al.,
2005).
Another randomized trial attempted to address the importance
of concurrent temozolomide without adjuvant drug (Kocher et al.,
2008). This German study randomized patients after gross total
resection to radiotherapy alone or radiotherapy with concurrent
but no adjuvant temozolomide. Progression-free survival in the
radiation alone arm was 7months compared to 6months with
radiation and temozolomide. No difference in overall survival was
observed with chemoradiation over radiation alone, with median
overall survival of 15 and 17months, respectively. The study was
stopped early after the results of the EORTC study were released.
The authors argued the negative result may have been a conse-
quence of the small sample size, although the possibility that the
simultaneous portion of temzolomide therapy had less impact on
survival than the adjuvant component could not be excluded. A
signiﬁcant proportion of patients received the drug later at time of
progressionwhichmay explain the absence of a survival difference;
also, this trial did not reportwhether or not the armswere balanced
by MGMT methylation.
Given the signiﬁcance of MGMT in determining outcome,
MGMT-depleting strategies are clearly attractive; in this context,
speciﬁc agents to inhibit MGMT have been developed, such as
Patrin2, O-6BG, and methoxyamine, but, when used in combi-
nation with alkylating agents result in inordinate toxicity such
as myelosuppression, requiring considerable temozolomide dose
reductions (Liu and Gerson, 2004; Warren et al., 2005; Sabhar-
wal and Middleton, 2006; Woolford et al., 2006). MGMT may
also be depleted through enzymatic supply exhaustion since every
repair event consumes a molecule of MGMT and irreversibly
methylates it. RTOG 0525 compared conventional adjuvant temo-
zolomide with dose-intensive therapy in patients with newly diag-
nosed glioblastoma,with the hypothesis that the continuous dose-
adjuvant approach in the adjuvant setting would lead to MGMT
depletion and superior outcomes (Gilbert et al., 2011). In addi-
tion the study prospectively looked at the question of whether
methylation of the MGMT promoter leads to improved outcome
with temozolomide treatment. No beneﬁt was observed for inten-
siﬁed temozolomide regardless of methylation status, although the
importance of MGMT methylation as a prognostic factor in GBM
was conﬁrmed.
TARGETED THERAPY
Signiﬁcant progress has been made recently in molecular charac-
terization of glioblastoma. Historically, two subtypes have been
deﬁned based on molecular and genetic characteristics (Wen and
Kesari, 2008; Anonymous, 2008). Primary glioblastomas typi-
cally present in patients over 50 years, have loss of heterozy-
gosity of chromosome 10q, EGFR ampliﬁcation, and deletion
of PTEN and p16. The Cancer Genome Atlas consortium work
on glioblastoma also provided preliminary evidence that pri-
mary glioblastoma could be divided into four subtypes: classi-
cal, mesenchymal, neural, and proneural. The classical subtype
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demonstrates response to radiation and chemotherapy, puta-
tively a response consequential to intact p53 pathways. This sub-
type also demonstrates increased expression in Notch and Sonic
Hedgehog signaling pathways. The second type is associated with
mesenchyme and angiogenesis, has frequent inactivation of p53,
PTEN, and NF1, responds to aggressive chemoradiation, and may
respond to Ras, PI3K, and angiogenesis inhibitors. The proneural
subtype has superior survival compared to the other three types yet
shows the least response to classical treatments. The neural sub-
type is the least deﬁned and has gene expression signatures similar
to that in normal brain. Secondary glioblastomas are typically
transformations of lower grade gliomas in younger patients and
possess p53 mutations, overexpression of PDGFR, abnormalities
in the p16 and pRb pathways, and loss of heterozygosity of 10q.
Approximately half of patients with primary glioblastoma and
EGFR ampliﬁcation express EGFRvIII, a mutated form of EGFR
that has a severely truncated extra-cellular ligand-binding domain.
Downstream pathways activated by EGFR signaling include the
PI3K–Akt–mTOR pathway, involved in cell growth and death. The
tumor suppressor gene PTEN is an inhibitor of the PI3K pathway
and is inactivated in 40 to 50% of glioblastomas. These path-
ways, when active, may in turn lead to upregulation of vascular
endothelial growth factor (VEGF) and angiogenesis.
Single agent targeted therapies typically result in response
rates below 20% with no improvement in 6-month progression-
free survival. Phase II testing of erlotinib in newly diagnosed
glioblastoma concurrently with temozolomide was not effective
and yielded unacceptable toxicity (Table 4; Peereboom et al.,
2010). In a study by Mellinghoff, patients with recurrent malig-
nant gliomas who received EGFR tyrosine kinase inhibitors were
analyzed (Mellinghoff et al., 2005). The authors noted that clinical
response to the kinase inhibitorswas associatedwith co-expression
of EGFRvIII and wild-type PTEN, highlighting a possible route to
genetically characterize a subgroup of patients who would ben-
eﬁt from targeted agents. Recently, a vaccine against EGFRvIII,
rindopepimut, has been evaluated in three small phase I/II studies
(http://www.celldextherapeutics.com/wt/page/cdx_110., f). The
ACT III trial studied rindopepimut in patients with newly diag-
nosed glioblastoma following gross total resection and treatment
with temozolomide and radiation. This built on the study of
rindopepimut vaccine alone (ACTIVATE) and rindopepimut with
temozolomide (ACT II), with preliminary results demonstrat-
ing increased time to progression and overall survival compared
to historical controls. Initial results of ACT III showed signiﬁ-
cant improvement in progression-free rate over a predetermined
estimate, irrespective of MGMT expression status.
Malignant gliomas are highly vascular tumors, and studies with
older antiangiogenic agents such as thalidomide did not show
signiﬁcant activity. Bevacizumab is a humanizedmonoclonal anti-
body against VEGF that prevents endothelial cell proliferation
and migration. In the recurrent glioblastoma, bevacizumab com-
bined with irinotecan showed 6-month progression-free survival
of 46% and overall survival of 77% with only moderate toxicity
(Vredenburgh et al., 2007). In AVF3708g, a phase II trial for recur-
rent glioblastoma, Friedman et al. (2009) studied bevacizumab
alone and in combination with irinotecan. The authors showed
a 6-month progression-free survival of 42.6% with single agent
bevacizumab and 50.3% for combination therapy, and median
overall survival times were an impressive 9.2 and 8.7months,
respectively. The single-arm, single-site NCI 06-C-0064E study
of single agent bevacizumab in recurrent disease also showed a
durable median response of 3.9months (Kreisl et al., 2009). The
FDA recently approved use of bevacizumab as monotherapy in
recurrent glioblastoma on the basis of the favorable responses to
single agent bevacizumab in these studies.
RTOG 08-25, and AVAGLIO are two ongoing phase III tri-
als comparing concurrent radiation and temozolomide with and
without bevacizumab. A recent phase II study of bevacizumab
and temozolomide during and after radiation for newly diagnosed
glioblastoma found a 13.6-month progression-free survival and
19.6month overall survival, an improvement in progression-free
survival over theUCLA/KPLAcontrol cohort (6.9months) but not
in overall survival. The authors suggested that since many patients
in the control cohort received bevacizumab at recurrence that
bevacizumab at progression may provide the same survival bene-
ﬁt as ﬁrst-line treatment (Lai et al., 2011). Until mature results of
phase III trials become available, bevacizumab should not be con-
sidered as having a proven role in the up-front treatment setting.
Table 4 | Novel targets and trials for GBM.
Target Agent Mechanism of action Comments
VEGFR Bevacizumab Monoclonal antibody against
VEGFR
Active in glioblastoma, activity in newly diagnosed glioblastoma being
prospectively evaluated in RTOG 08-25
VEGFR Cediranib pan-VEGF receptor inhibitor No improvement in survival in combination with lomustine over lomustine
alone
MET, VEGFR-2 XL-184 pan-tyrosine kinase inhibitor Phase II study ongoing
EGFR Geﬁtinib, erlotinib Receptor tyrosine kinase
inhibitors
Geﬁtinib+RT not superior to RT alone, erlotinib+RT+temozolomide being
evaluated
EGFR Rindopepimut Vaccine to EGFRvIII Active in glioblastoma, being studied in ACT III study
PARP-1 Iniparnib Poly(ADP-ribose)
polymerase-1 inhibitor
Reversed temozolomide resistance in a murine xenograft
Integrin alpha-v/beta-3
and alpha-v/beta-5
Cilengitide Inhibits alpha-v integrin sig-
naling
Phase III study comparing cilengitide to conventional chemoradiation versus
conventional treatment alone ongoing
Notch pathway GSI RO4929097 Gamma secretase inhibitor Phase II study ongoing
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Unlike bevacizumab, which is a humanized monoclonal anti-
body against all isoforms of VEGF, cediranib is a pan-VEGFR
receptor tyrosine kinase inhibitor. A phase II trial of cediranib
showed greater than a 50% radiographic response rate (Batchelor
et al., 2010). However, the randomized REGAL study of cediranib
alone or in combination with lomustine failed to show improved
progression-free or overall survival compared to lomustine alone
for patients with recurrent GBM; a phase II randomized trial of
cediranib, temozolomide and radiotherapy for newly diagnosed
GBM is currently being conducted by the RTOG (Stupp et al.,
2010). XL-184 is a pan-tyrosine kinase inhibitor whose principal
targets are VEGFR-2 and MET; NCT00704288, a phase II study of
this drug in progressive or recurrent glioblastoma has just been
completed (Zhang et al., 2010).
With recent evidence that endothelial integrins interact with
extra-cellular ligands to promote angiogenesis, a class of inhibitors
has been developed to target alpha-v/beta-3 and alpha-v/beta-5
integrins (Silvestre et al., 2005). Cilengitide is a novel compound
selective for alpha-v integrins under investigation as an antian-
giogenic agent. The combination of cilengitide with conventional
chemoradiation versus chemoradiation alone for newly diagnosed
GBM is being investigated in the phase III CENTRIC trial.
PARP inhibitors are a novel class of compounds which have
demonstrated activity in solid tumors. Alkylation by temozolo-
mide more often targets the N-7 guanine and N-3 adenine over
the O-6 guanine, and the former two events are repaired by
enzymes in the base excision pathway which can be inhibited by
PARP inhibitors. In a mouse xenograft model, PARP-1 inhibition
reversed temozolomide resistance, suggesting that PARP inhibitors
may improve efﬁcacy of temozolomide particularly in tumorswith
mismatch repair defects (Cheng et al., 2005). NCT00687765 is a
phase I clinical trial studying a poly (ADP-ribose) polymerase-
1 (PARP-1) inhibitor, BSI-201, also known as iniparnib. Patients
with newly diagnosed glioblastoma will ﬁrst receive conventional
radiotherapy and temozolomide, which will be followed by adju-
vant temozolomide and iniparnib. TheNCCTG,RTOG,andABTC
are also evaluating PARP inhibitors in GBM.
Another signaling pathway that may be a malignant glioma
treatment target is Notch, which is involved in stem cell differ-
entiation (Lino et al., 2010). New data suggest that tumor stem
cells may be important as progenitors of malignant gliomas and
may constitute radio- and possibly chemo-resistant clones that
contribute to resistance of malignant gliomas to conventional
treatments (Vescovi et al., 2006; Dirks, 2008). Notch pathway
inhibition with gamma secretase inhibitors (GSIs) reduces glial
stem cell proliferation and increased apoptosis associated with
decreased Akt and Stat3 phosphorylation. A new phase II clinical
trial, NCT01122901, is studying GSI RO4929097 in recurrent or
progressive glioblastoma.
CONCLUSION
Despitemedian survival in patientswith newly diagnosed glioblas-
toma of around 1 year, signiﬁcant progress in the treatment of this
malignancy over the past few decades has been made. Reﬁned sur-
gical techniques have improved extent of resection and decreased
surgical morbidity. A shift from whole brain to partial brain radi-
ation with a boost focused on the tumor bed did not compromise
rates of local and marginal tumor control. Still, dose escalation
beyond 60Gy using radiosurgery, brachytherapy, or fractionated
external beam approaches with nitrosoureas, has not demon-
strated improved survival or reduced rates of local failure. With
the advent of temozolomide, new opportunities for improved out-
come have emerged. Molecular characterization of glioblastoma
is allowing deﬁnition of subgroups of patients most likely to ben-
eﬁt from particular therapies. Numerous targeted agents aimed
at a broad array of intra- and extra-cellular targets are currently
in clinical trials with the hope that new and even more effective
therapies will be discovered.
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